share_log

四環醫藥:截至二零二四年一月三十一日止之股份發行人的證券變動月報表

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

香港交易所 ·  Feb 1 03:03
Summary by Moomoo AI
四環醫藥(四环医药)於2024年1月31日提交了最新的證券變動月報表,向香港交易及結算所有限公司報告其股份及股份期權的最新變動情況。報告顯示,四環醫藥的法定/註冊股本及已發行股份在2024年1月份均無變動,維持在1,000,000,000港元及9,329,999,206股。此外,根據2017年10月24日採納的股份期權計劃,公司目前有74,110,000股份期權未行使,以及7,500,000股份期權未行使,行使價分別為0.972港元和2.22港元。報告中未提及其他有關股份的變動,並確認所有證券發行均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的要求。
四環醫藥(四环医药)於2024年1月31日提交了最新的證券變動月報表,向香港交易及結算所有限公司報告其股份及股份期權的最新變動情況。報告顯示,四環醫藥的法定/註冊股本及已發行股份在2024年1月份均無變動,維持在1,000,000,000港元及9,329,999,206股。此外,根據2017年10月24日採納的股份期權計劃,公司目前有74,110,000股份期權未行使,以及7,500,000股份期權未行使,行使價分別為0.972港元和2.22港元。報告中未提及其他有關股份的變動,並確認所有證券發行均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的要求。
Four Circles Pharmaceuticals filed its latest Securities Monthly Change Report on 31 January 2024 to report the latest changes in its shares and share options to Hong Kong Trading and Settlement Limited. The report shows that the regulated/registered share capital and issued shares of 4 Circle Pharmaceuticals remained unchanged in January 2024 at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on 24 October 2017, the Company currently has 74,110,000 share options outstanding and 7,500,000 share options unexercised at an exercise price of HK$0.972 and HK$2.22, respectively. The report does not mention any other changes in the shares concerned and confirms that all securities issuance has been approved by the Board and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Four Circles Pharmaceuticals filed its latest Securities Monthly Change Report on 31 January 2024 to report the latest changes in its shares and share options to Hong Kong Trading and Settlement Limited. The report shows that the regulated/registered share capital and issued shares of 4 Circle Pharmaceuticals remained unchanged in January 2024 at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on 24 October 2017, the Company currently has 74,110,000 share options outstanding and 7,500,000 share options unexercised at an exercise price of HK$0.972 and HK$2.22, respectively. The report does not mention any other changes in the shares concerned and confirms that all securities issuance has been approved by the Board and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more